VIDA Diagnostics, Inc. (VIDA), the leader in imaging intelligence, has announced the availability of VIDA Intelligence Portal 2.0, a major upgrade to its cloud-native, AI-enabled intelligence platform. The newly upgraded platform increases efficiency in clinical trial imaging by streamlining staff training, image data acquisition and data quality, curation, and management. New digital onboarding features in VIDA Intelligence Portal 2.0 greatly simplify the trial site registration process.
“We are thrilled that sponsors and trial sites around the world are embracing the VIDA Intelligence Portal,” said Todd Johnson, CTO of VIDA. “We are proud to expand patient access to novel therapy options by enabling new sites to participate in imaging-based clinical trials with complete confidence in the quality of their image acquisition, staff training, and readiness.”
The global network of sites equipped with VIDA Intelligence Portal has grown to more than 1,000 in less than a year since its release. Hospitals and now imaging centers work with VIDA to participate in clinical trials. This group includes RAYUS Radiology, a national provider of advanced diagnostic and interventional radiology with 150 sites. Several other groups of imaging centers in the United States and Europe have also reached agreements with VIDA in the last month.
VIDA has an aggressive roadmap for the VIDA Intelligence Portal, including several new data intelligence services to further accelerate clinical trials. For example, VIDA is well positioned to intelligently identify qualified sites for new trial opportunities.
At the forefront of this development of VIDA Intelligence Portal is an expert in cloud-based imaging platforms. “I am passionate about developing innovative, secure cloud products that improve our lives; improving and accelerating clinical trials is a catch for me,” said Michel Blaha, VP of Engineering, VIDA, who recently joined the company to lead the development of the VIDA portal. “On my debut at VIDA, I experienced the passion of this team and, just as important, I learned how transformative our platform is for customers and for the patients they serve.”
